-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Intercept Pharmaceuticals, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2019 to 2022.
- Intercept Pharmaceuticals, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2023 was -0.07 USD/shares, a 101% decline year-over-year.
- Intercept Pharmaceuticals, Inc. Earnings Per Share, Diluted for the twelve months ending September 30, 2023 was -1.48 USD/shares, a 126% decline year-over-year.
- Intercept Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2022 was 6.56 USD/shares.
- Intercept Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2021 was -2.87 USD/shares, a 65.6% increase from 2020.
- Intercept Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2020 was -8.34 USD/shares, a 23.4% increase from 2019.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)